====== Gliosarcoma treatment ======

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1rG1EERZjlGw8m7owSCGNj3i9WmlOd3CWYdKjTZADnCPz0sIV0/?limit=15&utm_campaign=pubmed-2&fc=20250226062203}}

see also [[glioblastoma treatment]].
----
 Good surgical excision is a favorable prognostic factor for the outcome of GSM. Gliosarcoma which resembles meningioma has got better survival outcome compared to the one that resembles glioblastoma
((Nayak R, Akash J, Patel B, Gandham EJ, Krishnaprabhu R. Primary Gliosarcoma: A 15-Year Experience at a Tertiary Care Center. Neurol India. 2024 Nov 1;72(6):1213-1217. doi: 10.4103/neurol-india.Neurol-India-D-24-00804. Epub 2024 Dec 17. PMID: 39690994.))
----


In a national analysis of [[gliosarcoma]] patients, [[temozolomide]] was associated with prolonged OS irrespective of [[MGMT]] status. These results provide support for the current practice of trimodal therapy for gliosarcoma
((Kavouridis VK, Ligon KL, Wen PY, Iorgulescu JB. Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. J Neurooncol. 2022 Apr 26. doi: 10.1007/s11060-022-04016-5. Epub ahead of print. PMID: 35474499.)).
----
Due to its rarity, the optimal therapy of GS have been based on small retrospective cohort studies, with treatment presently utilizing regimens established for other high-grade gliomas, including combination of resection, radiotherapy and temozolomide-based chemotherapy. As more information is gathered about GS molecular profiles, novel treatment strategies may be developed to improve outcomes of GS patients
((McAleer MF, Brown PD. Therapeutic management of gliosarcoma in the temozolomide era. CNS Oncol. 2015;4(3):171-8. doi: 10.2217/cns.14.61. Epub 2015 Apr 23. PMID: 25905568; PMCID: PMC6088332.)).